{'fraction_non_alphanumeric': 0.025538707102952914, 'fraction_numerical': 0.018355945730247406, 'mean_word_length': 5.207920792079208, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Therapeutic Effect of Chondroitin Polysulphate in Elderly Atherosclerotic Patients

The therapeutic effect of chondroitin polysulphate (CPS) in atherosclerosis was clinically investigated following oral administration to 46 elderly age-matched patients. Half of the patients received CPS in a daily dose of 3 g and the remaining patients received placebo treatment. The treatment period varied between 6 and 64 months. During the study 4 patients died; 3 had been receiving placebo treatment and 1 had been receiving CPS. In a control group of 40 completely untreated elderly patients, matched for age, there were, by comparison, 16 deaths. Serum cholesterol measured in the CPS-treated group, fell to mean values between 10% and 20% lower than the pre-treatment values and serum triglyceride fell, significantly, to mean values 27% lower than those of controls. After 3 months of CPS treatment, mean clotting time was prolonged by 50%. In 1 patient with angina pectoris there was marked electrocardiographic evidence of improvement, with diminution of ST depression. No side-effects attributable to the medication were recorded during the study. The anti-lipaemic and anti-thrombogenic properties of CPS were thus demonstrated in clinical practice.